* Olema Pharmaceuticals Inc OLMA.OQ reported a quarterly
adjusted loss of 65 cents per share for the quarter ended in
December. The mean expectation of five analysts for the quarter
was for a loss of 65 cents per share.
* Reported revenue was zero; analysts expected zero.
* Olema Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 65 cents.
* The mean earnings estimate of analysts had fallen by
about 0.3%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
* Olema Pharmaceuticals Inc shares had risen by 58.8% this
quarter.
* The company reported a quarterly loss of $26.18 million.
* Wall Street's median 12-month price target for Olema
Pharmaceuticals Inc is $12.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
This summary was machine generated from LSEG Refinitiv data
March 9 at 09:26 p.m. UTC. All figures in US dollars unless
otherwise stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2022 -0.65 -0.65 Met
Sep. 30 2022 -0.77 -0.57 Beat
Jun. 30 2022 -0.64 -0.82 Missed
Mar. 31 2022 -0.57 -0.58 Missed